Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach

被引:66
作者
Ziemssen, Tjalf [1 ]
Kern, Raimar [1 ]
Thomas, Katja [1 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Neurol, MS Ctr Dresden,Ctr Clin Neurosci, Fetscherstr 74, D-01307 Dresden, Germany
来源
BMC NEUROLOGY | 2016年 / 16卷
关键词
Multiple sclerosis; Personalized medicine; Multiple Sclerosis Documentation System; PATIENT-REPORTED OUTCOMES; LONG-TERM; MANAGEMENT-SYSTEM; DISEASE-ACTIVITY; UK MS; REGISTRY; CLASSIFICATION; DISABILITY; DESIGN; TRIALS;
D O I
10.1186/s12883-016-0639-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Multiple sclerosis (MS) is a highly heterogeneous disease as it can present inter-individually as well as intra-individually, with different disease phenotypes emerging during different stages in the long-term disease course. In addition to advanced immunological, genetic and magnetic resonance imaging (MRI) profiling of the patient, the clinical profiling of MS patients needs to be widely implemented in clinical practice and improved by including a greater range of relevant parameters as patient-reported outcomes. It is crucial to implement a high standard of clinical characterization of individual patients as this is key to effective long-term observation and evaluation. To generate reliable real-world data, individual clinical data should be collected in specific MS registries and/or using intelligent software instruments as the Multiple Sclerosis Documentation System 3D. Computational analysis of biological processes will play a key role in the transition to personalized MS treatment. Major breakthroughs in the areas of bioinformatics and computational systems biology will be required to process this complex information to enable improved personalization of treatment for MS patients.
引用
收藏
页数:10
相关论文
共 69 条
[51]  
Salaffi F, 2009, CLIN EXP RHEUMATOL, V27, P459
[52]  
Schultheiss T, 2012, NERVENARZT, V83, P450, DOI 10.1007/s00115-011-3376-6
[53]   Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis [J].
Sonder, Judith M. ;
Balk, Lisanne J. ;
van der Linden, Femke A. H. ;
Bosma, Libertje V. A. E. ;
Polman, Chris H. ;
Uitdehaag, Bernard M. J. .
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (14) :1865-1871
[54]   Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model [J].
Stangel, Martin ;
Penner, Iris Katharina ;
Kallmann, Boris A. ;
Lukas, Carsten ;
Kieseier, Bernd C. .
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) :3-13
[55]   Management of fingolimod in clinical practice [J].
Thomas, Katja ;
Ziemssen, Tjalf .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 :S60-S64
[56]   The natural history of primary progressive MS in British Columbia, Canada [J].
Tremlett, H ;
Paty, D ;
Devonshire, V .
NEUROLOGY, 2005, 65 (12) :1919-1923
[57]   Personalized cardiovascular medicine: concepts and methodological considerations [J].
Voelzke, Henry ;
Schmidt, Carsten O. ;
Baumeister, Sebastian E. ;
Ittermann, Till ;
Fung, Glenn ;
Krafczyk-Korth, Janina ;
Hoffmann, Wolfgang ;
Schwab, Matthias ;
Schwabedissen, Henriette E. Meyer zu ;
Doerr, Marcus ;
Felix, Stephan B. ;
Lieb, Wolfgang ;
Kroemer, Heyo K. .
NATURE REVIEWS CARDIOLOGY, 2013, 10 (06) :308-316
[58]  
Vollmer T.L., 1999, International Journal of MS Care, V1, P28, DOI [DOI 10.7224/1537-2073-1.1.28, 10.7224/1537-2073-1.1, DOI 10.7224/1537-2073-1.1]
[59]  
Weathers Allison L, 2013, Neurol Clin Pract, V3, P141, DOI 10.1212/CPJ.0b013e31828d9fb7
[60]  
Ziemssen T, 2016, BMC NEUROL IN PRESS